Kazuki Yano
Tokai University(JP)
Publications by Year
Research Areas
Bone Metabolism and Diseases, Bone health and treatments, Bone health and osteoporosis research, Inflammatory mediators and NSAID effects, TGF-β signaling in diseases
Most-Cited Works
- → Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL(1998)4,244 cited
- → Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesisin Vitro1(1998)1,206 cited
- → Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis(1997)791 cited
- → Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/Osteoprotegerin(1998)773 cited
- → Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients(2001)421 cited
- → Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis(1999)366 cited
- → Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells(1998)302 cited
- → Osteoclast Differentiation Factor Mediates an Essential Signal for Bone Resorption Induced by 1α,25-Dihydroxyvitamin D3, Prostaglandin E2, or Parathyroid Hormone in the Microenvironment of Bone(1998)239 cited
- → Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure(2002)167 cited
- → Induction of Osteoclast Differentiation by Runx2 through Receptor Activator of Nuclear Factor-κB Ligand (RANKL) and Osteoprotegerin Regulation and Partial Rescue of Osteoclastogenesis in Runx2–/– Mice by RANKL Transgene(2003)161 cited